+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benexate Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Benexate Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Benexate Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082820
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benexate Market grew from USD 584.38 million in 2024 to USD 625.71 million in 2025. It is expected to continue growing at a CAGR of 6.94%, reaching USD 874.43 million by 2030.

Benexate has emerged as a pivotal compound in pain management, offering clinicians and patients a versatile solution across acute, chronic, and neuropathic indications. Its favorable pharmacokinetic profile and innovative delivery formats have driven rapid adoption in key markets. This executive summary distills insights from a rigorous assessment of recent regulatory shifts, supply-chain disruptions, and competitive dynamics. It sets the stage for strategic decision-making by spotlighting the most consequential trends, examining tariff implications, and unpacking granular segmentation perspectives. Readers will gain a clear understanding of how evolving healthcare paradigms and market forces are shaping benexate’s trajectory, equipping stakeholders with the knowledge needed to capitalize on emerging opportunities.

Transformative Shifts in the Landscape

The landscape for benexate has been reshaped by several transformative forces. First, personalized medicine initiatives are driving demand for tailored dosing regimens and advanced formulations, compelling manufacturers to invest in extended-release oral tablets and targeted injectable pre-filled syringes. Second, digital health platforms and telepharmacy services are streamlining prescription fulfillment and patient monitoring, reducing time to therapy and enhancing adherence. Third, regulatory frameworks are evolving to accommodate real-world evidence submissions, accelerating approval pathways for novel formulations such as gel-based topical ointments. Finally, sustainability mandates are prompting a shift toward eco-friendly packaging and greener manufacturing processes, which in turn influence procurement strategies and supplier partnerships. Together, these shifts are redefining supply-chain resilience and competitive positioning, underscoring the need for proactive innovation and agile operational models.

Cumulative Impact of United States Tariffs 2025

Anticipated U.S. tariffs set to take effect in 2025 will have a cascading impact on benexate’s value chain. Increased duties on active pharmaceutical ingredients sourced from key exporting nations elevate production costs, particularly for companies reliant on vials and raw precursors imported from Asia. These cost pressures are likely to be passed downstream, prompting wholesalers and hospitals to re-evaluate sourcing contracts and inventory management practices. In response, several players are exploring the repatriation of certain manufacturing processes to North America, while others are negotiating long-term purchasing agreements to lock in favorable exchange rates. Additionally, shifting tariff classifications for packaging components such as aluminum syringes and plastic cartridge systems may necessitate product redesigns to mitigate duty exposure. This confluence of factors underscores the importance of cross-functional collaboration between procurement, finance, and regulatory affairs teams to safeguard margins and maintain uninterrupted patient access.

Key Segmentation Insights

A nuanced view of benexate’s market reveals distinct performance patterns across multiple segmentation dimensions. When analyzed by product type, the market encompasses injectable solutions split between pre-filled syringes and vials, oral tablets differentiated by extended-release and immediate-release formulations, and topical ointments available as cream-based, gel-based, or patch-based preparations. Application areas span acute pain management-including injury-induced and post-surgical pain-chronic pain management such as arthritis, back, and cancer pain, and neuropathic conditions like diabetic neuropathy and post-herpetic neuralgia. Distribution channels range from private and public hospitals to online pharmacies operating via e-pharma platforms, as well as chain and independent retail pharmacies. End-user categories divide into adults-further segmented into the elderly and working professionals-and pediatric patients, covering children and infants. Additional layers of analysis include therapeutic class distinctions between analgesics and antipyretics and treatment duration choices of short-term versus long-term therapy. Cross-segment synergies point to high-value opportunities in extended-release tablets for chronic indications, injectable solutions for acute hospital-based care, and cream-based topical formulations suited for outpatient neuropathic pain management.

Key Regional Insights

Regional performance of benexate exhibits divergent growth drivers and adoption trajectories. In the Americas, robust hospital infrastructures and widespread telehealth integration have accelerated uptake of pre-filled syringes and extended-release tablets, particularly within private hospital networks. Meanwhile, Europe, Middle East & Africa display heightened interest in cream-based and gel-based topical ointments driven by stringent regulatory emphasis on safety and patient convenience, alongside growing demand in post-surgical and neuropathic applications. In Asia-Pacific, expanding e-pharmacy platforms and growing retail pharmacy penetration are fueling rapid growth of immediate-release tablets and patch-based topical systems, with emerging markets placing a premium on cost-effective short-term therapies. While reimbursement policies and regulatory pathways vary widely, all regions signal a collective push toward integrated care models that blend digital monitoring with optimized delivery formats.

Key Companies Insights

Competitive dynamics in the benexate market are shaped by a mix of global powerhouses and specialized players. Astellas Pharma and Takeda Pharmaceutical leverage extensive R&D pipelines to advance next-generation oral and injectable formulations. Chugai Pharmaceutical and Daiichi Sankyo, backed by strong partnerships, focus on biosimilar development and strategic licensing agreements. Eisai and Kyowa Kirin differentiate through proprietary gel-and patch-based delivery technologies, while Meiji Seika Pharma and Mitsubishi Tanabe Pharma emphasize sustainability in manufacturing and eco-friendly packaging innovations. Nipro Corporation and Nichi-Iko Pharmaceutical capitalize on cost-efficiency in large-scale production of vials and immediate-release tablets, whereas Otsuka Pharmaceutical and Sawai Pharmaceutical deliver targeted outreach in emerging markets via digital channels. Shionogi & Co. and Teijin Pharma apply advanced real-world data analytics to optimize chronic pain regimens, and Towa Pharmaceutical exploits niche positioning in pediatric and elderly formulations. This varied landscape underscores the importance of strategic alliances, portfolio diversification, and technology licensing to maintain competitive advantage.

Actionable Recommendations for Industry Leaders

Industry leaders should consider a multi-pronged approach to capture benexate’s full potential. First, diversifying supply sources by establishing regional manufacturing hubs can neutralize tariff impacts and reduce lead times. Second, prioritizing next-generation formulations-especially extended-release tablets and gel-based ointments-will address unmet needs in chronic and neuropathic pain segments. Third, forging strategic alliances with digital health providers can enhance patient engagement, adherence tracking, and remote monitoring capabilities. Fourth, pursuing proactive regulatory dialogues to leverage real-world evidence frameworks can expedite approval of new delivery formats. Fifth, optimizing commercial models through differentiated pricing strategies for private hospitals, e-pharma platforms, and retail chains will improve market penetration. Finally, committing to sustainability initiatives in packaging and carbon footprint reduction will resonate with payers and regulators, reinforcing brand reputation and long-term viability.

Conclusion

The benexate market stands at the intersection of innovation, regulatory evolution, and shifting global trade dynamics. Stakeholders who strategically harness segmentation insights, regional nuances, and competitive intelligence will be well positioned to mitigate risks and seize growth opportunities. By investing in advanced delivery technologies, digital health integrations, and sustainable practices, companies can solidify their foothold across acute, chronic, and neuropathic pain arenas. Collaboration across functional teams-spanning R&D, regulatory affairs, procurement, and commercial operations-will be critical to navigate tariff challenges and evolving reimbursement landscapes. Ultimately, a focused execution of these strategies will drive patient access, optimize cost efficiencies, and deliver long-term value for all participants in the benexate ecosystem.

Market Segmentation & Coverage

This research report categorizes the Benexate Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Injectable Solutions
    • Pre-Filled Syringes
    • Vials
  • Oral Tablets
    • Extended-Release
    • Immediate-Release
  • Topical Ointments
    • Cream-Based
    • Gel-Based
    • Patch-Based
  • Acute Pain Management
    • Injury-Induced Pain
    • Post-Surgical Pain
  • Chronic Pain Management
    • Arthritis Pain
    • Back Pain
    • Cancer Pain
  • Neuropathic Pain
    • Diabetic Neuropathy
    • Post-Herpetic Neuralgia
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Online Pharmacies
    • E-Pharma Platforms
  • Retail Pharmacies
    • Chain Pharmacies
    • Independent Pharmacies
  • Adults
    • Elderly Population
    • Working Professionals
  • Pediatric
    • Children
    • Infants
  • Analgesics
  • Antipyretics
  • Long-Term Therapy
  • Short-Term Therapy

This research report categorizes the Benexate Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Benexate Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Astellas Pharma Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • Meiji Seika Pharma Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Nipro Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Sawai Pharmaceutical Co., Ltd.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Towa Pharmaceutical Co., Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benexate Market, by Product Type
8.1. Introduction
8.2. Injectable Solutions
8.2.1. Pre-Filled Syringes
8.2.2. Vials
8.3. Oral Tablets
8.3.1. Extended-Release
8.3.2. Immediate-Release
8.4. Topical Ointments
8.4.1. Cream-Based
8.4.2. Gel-Based
8.4.3. Patch-Based
9. Benexate Market, by Application
9.1. Introduction
9.2. Acute Pain Management
9.2.1. Injury-Induced Pain
9.2.2. Post-Surgical Pain
9.3. Chronic Pain Management
9.3.1. Arthritis Pain
9.3.2. Back Pain
9.3.3. Cancer Pain
9.4. Neuropathic Pain
9.4.1. Diabetic Neuropathy
9.4.2. Post-Herpetic Neuralgia
10. Benexate Market, by Distribution Channel
10.1. Introduction
10.2. Hospitals
10.2.1. Private Hospitals
10.2.2. Public Hospitals
10.3. Online Pharmacies
10.3.1. E-Pharma Platforms
10.4. Retail Pharmacies
10.4.1. Chain Pharmacies
10.4.2. Independent Pharmacies
11. Benexate Market, by End User
11.1. Introduction
11.2. Adults
11.2.1. Elderly Population
11.2.2. Working Professionals
11.3. Pediatric
11.3.1. Children
11.3.2. Infants
12. Benexate Market, by Therapeutic Class
12.1. Introduction
12.2. Analgesics
12.3. Antipyretics
13. Benexate Market, by Treatment Duration
13.1. Introduction
13.2. Long-Term Therapy
13.3. Short-Term Therapy
14. Americas Benexate Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Benexate Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Benexate Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Astellas Pharma Inc.
17.3.2. Chugai Pharmaceutical Co., Ltd.
17.3.3. Daiichi Sankyo Co., Ltd.
17.3.4. Eisai Co., Ltd.
17.3.5. Kyowa Kirin Co., Ltd.
17.3.6. Meiji Seika Pharma Co., Ltd.
17.3.7. Mitsubishi Tanabe Pharma Corporation
17.3.8. Nichi-Iko Pharmaceutical Co., Ltd.
17.3.9. Nipro Corporation
17.3.10. Otsuka Pharmaceutical Co., Ltd.
17.3.11. Sawai Pharmaceutical Co., Ltd.
17.3.12. Shionogi & Co., Ltd.
17.3.13. Takeda Pharmaceutical Company Limited
17.3.14. Teijin Pharma Limited
17.3.15. Towa Pharmaceutical Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BENEXATE MARKET MULTI-CURRENCY
FIGURE 2. BENEXATE MARKET MULTI-LANGUAGE
FIGURE 3. BENEXATE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BENEXATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BENEXATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENEXATE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENEXATE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BENEXATE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BENEXATE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BENEXATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BENEXATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BENEXATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BENEXATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BENEXATE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENEXATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENEXATE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENEXATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENEXATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENEXATE MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENEXATE MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENEXATE MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENEXATE MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENEXATE MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENEXATE MARKET SIZE, BY CREAM-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENEXATE MARKET SIZE, BY GEL-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENEXATE MARKET SIZE, BY PATCH-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENEXATE MARKET SIZE, BY INJURY-INDUCED PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENEXATE MARKET SIZE, BY POST-SURGICAL PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENEXATE MARKET SIZE, BY ARTHRITIS PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENEXATE MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENEXATE MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENEXATE MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENEXATE MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BENEXATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BENEXATE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BENEXATE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BENEXATE MARKET SIZE, BY E-PHARMA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BENEXATE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BENEXATE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BENEXATE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BENEXATE MARKET SIZE, BY ELDERLY POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BENEXATE MARKET SIZE, BY WORKING PROFESSIONALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BENEXATE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BENEXATE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BENEXATE MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BENEXATE MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BENEXATE MARKET SIZE, BY ANTIPYRETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BENEXATE MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BENEXATE MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BENEXATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 113. CANADA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. CANADA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 115. CANADA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 116. CANADA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 117. CANADA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. CANADA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 119. CANADA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 120. CANADA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 121. CANADA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. CANADA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 123. CANADA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. CANADA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. CANADA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 127. CANADA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 128. CANADA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BENEXATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BENEXATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 200. CHINA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. CHINA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 202. CHINA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 203. CHINA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 204. CHINA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. CHINA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 206. CHINA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 207. CHINA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 208. CHINA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. CHINA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 210. CHINA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 211. CHINA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 212. CHINA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. CHINA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 214. CHINA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 215. CHINA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 216. CHINA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 217. INDIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. INDIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 219. INDIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 220. INDIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 221. INDIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. INDIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 223. INDIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 224. INDIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 225. INDIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. INDIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 227. INDIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. INDIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 229. INDIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. INDIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 231. INDIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 232. INDIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 233. INDIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 319. SOUTH KOREA BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. SOUTH KOREA BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 321. SOUTH KOREA BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 322. SOUTH KOREA BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 323. SOUTH KOREA BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. SOUTH KOREA BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 325. SOUTH KOREA BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 326. SOUTH KOREA BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 327. SOUTH KOREA BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. SOUTH KOREA BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 329. SOUTH KOREA BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 330. SOUTH KOREA BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 331. SOUTH KOREA BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. SOUTH KOREA BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 333. SOUTH KOREA BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 334. SOUTH KOREA BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 335. SOUTH KOREA BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 336. TAIWAN BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 337. TAIWAN BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 338. TAIWAN BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 339. TAIWAN BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 340. TAIWAN BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 341. TAIWAN BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 342. TAIWAN BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 343. TAIWAN BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 344. TAIWAN BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. TAIWAN BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 346. TAIWAN BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 347. TAIWAN BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 348. TAIWAN BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. TAIWAN BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 350. TAIWAN BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 351. TAIWAN BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 352. TAIWAN BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 353. THAILAND BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 354. THAILAND BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 355. THAILAND BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 356. THAILAND BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 357. THAILAND BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 358. THAILAND BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 359. THAILAND BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 360. THAILAND BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 361. THAILAND BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 362. THAILAND BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 363. THAILAND BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 364. THAILAND BENEXATE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 365. THAILAND BENEXATE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 366. THAILAND BENEXATE MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 367. THAILAND BENEXATE MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 368. THAILAND BENEXATE MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 369. THAILAND BENEXATE MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 370. VIETNAM BENEXATE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 371. VIETNAM BENEXATE MARKET SIZE, BY INJECTABLE SOLUTIONS, 2018-2030 (USD MILLION)
TABLE 372. VIETNAM BENEXATE MARKET SIZE, BY ORAL TABLETS, 2018-2030 (USD MILLION)
TABLE 373. VIETNAM BENEXATE MARKET SIZE, BY TOPICAL OINTMENTS, 2018-2030 (USD MILLION)
TABLE 374. VIETNAM BENEXATE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 375. VIETNAM BENEXATE MARKET SIZE, BY ACUTE PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 376. VIETNAM BENEXATE MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 377. VIETNAM BENEXATE MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2030 (USD MILLION)
TABLE 378. VIETNAM BENEXATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 379. VIETNAM BENEXATE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 380. VIETNAM BENEXATE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 381. VI

Companies Mentioned

  • Astellas Pharma Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • Meiji Seika Pharma Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Nipro Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Sawai Pharmaceutical Co., Ltd.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Towa Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Benexate Market by Product Type (Injectable Solutions, Oral Tablets, Topical Ointments), Application (Acute Pain Management, Chronic Pain Management, Neuropathic Pain), Distribution Channel, End-user, Therapeutic Class, Treatment Duration - Global Forecast 2025-2030 - Product Image

Benexate Market by Product Type (Injectable Solutions, Oral Tablets, Topical Ointments), Application (Acute Pain Management, Chronic Pain Management, Neuropathic Pain), Distribution Channel, End-user, Therapeutic Class, Treatment Duration - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Benexate (CAS 78718-52-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Benexate (CAS 78718-52-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Sodium Aluminum Belladonna Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Sodium Aluminum Belladonna Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global, United States Global, United States
From
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Gastroretentive Drug Delivery Systems Market Size, Share & Trends Analysis Report by Type (Floating, Expandable), Dosage (Tablets, Capsule, Gel, Liquid), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Gastroretentive Drug Delivery Systems Market Size, Share & Trends Analysis Report by Type (Floating, Expandable), Dosage (Tablets, Capsule, Gel, Liquid), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From

About the Market

Benexate is a medication used to treat gastrointestinal disorders. It is a proton pump inhibitor, meaning it reduces the amount of acid produced in the stomach. It is used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. It is also used to prevent stomach ulcers caused by certain medications. Benexate is available in both prescription and over-the-counter forms. Benexate is one of many medications used to treat gastrointestinal disorders. Other medications include antacids, H2 blockers, and prokinetics. These medications work in different ways to reduce stomach acid and treat symptoms of gastrointestinal disorders. The Benexate market is highly competitive, with many companies offering similar products. Some of the companies in the market include AstraZeneca, Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.